Results 121 to 130 of about 3,594 (173)
Some of the next articles are maybe not open access.
Aprepitant for Erlotinib-Induced Pruritus
New England Journal of Medicine, 2010To the Editor: Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic ...
Vincenzi B, Tonini G, Santini D
openaire +3 more sources
Drugs, 2009
Aprepitant (Emend) is a neurokinin-1 (NK(1)) receptor antagonist that is able to alleviate the emetic effects of substance P. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT(3) receptor antagonist (ondansetron), oral aprepitant (125 mg on day 1 then 80 mg once daily on days 2 and 3) was effective in the ...
Monique P, Curran, Dean M, Robinson
openaire +2 more sources
Aprepitant (Emend) is a neurokinin-1 (NK(1)) receptor antagonist that is able to alleviate the emetic effects of substance P. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT(3) receptor antagonist (ondansetron), oral aprepitant (125 mg on day 1 then 80 mg once daily on days 2 and 3) was effective in the ...
Monique P, Curran, Dean M, Robinson
openaire +2 more sources
Aprepitant: Review on Solubility Enhancement
Recent Advances in Drug Delivery and FormulationIntroduction: Substance P and its neurokinin (NK-1) receptors are upregulated in different pathophysiological conditions. Overexpression of the NK-1 receptor in cancer conditions has provided a promising pathway for cancer treatment. Clinically, Aprepitant (APT) is used as the only NK-1 antagonist in chemotherapy-induced nausea and vomiting (CINV ...
Lata, Kothapalli +6 more
openaire +2 more sources